Before a new pharmaceutical product can be marketed, it must first be tested in several phases of clinical trials. An Investigational New Drug (IND) application is a request submitted to the U.S. Food and Drug Administration (FDA) and provides the framework for clinical evaluation of an investigational product prior to marketing authorization. INDs are required for testing a drug or biologic in humans for the first time but also for clinical studies evaluating approved therapeutics outside of their labeled use (e.g., new indication, patient population, dosing regimen or formulation, or route of administration). Additionally, because approval under a marketing application, such as a New Drug Application (NDA) or Biologics Licensing Application (BLA), is required for a drug to be transported across states lines, authorization of an IND allows for an exemption from this requirement so that investigational products may be shipped to clinical investigators in different states.
All INDs are categorized as commercial or research INDs, depending upon the intended goals of the Sponsor, the entity initiating and taking responsibility for a clinical investigation. Commercial INDs are usually sponsored by pharmaceutical companies with the goal of gaining marketing approval of a pharmaceutical product, while research INDs are not intended to support an eventual marketing application and generally are sponsored by academic institutes or physicians for research purposes only. Though both categories of INDs require the same data to support the safety of the investigational product, commercial INDs must be submitted in the electronic common technical document (eCTD) format.
A critical document for an IND is the clinical protocol, which should include detailed plans regarding the purpose of the study, intended population (including how participants will be selected), proposed doses (including frequency and duration of dosing as well as route of administration), information to be collected, and the tests and procedures to be performed (to support both the purpose of the study and the safety of the participants). An IND must also include the qualifications of the clinical investigator(s) (generally physicians), to assess whether they are fit to fulfill the clinical trial duties for which they are responsible. For an initial IND, investigator information for at least one clinical site is needed; once the IND is active, additional clinical sites can be added through IND amendments. Other core components of an IND application include nonclinical, clinical pharmacology, and chemistry, manufacturing, and controls (CMC) information, as further described below. Depending on the investigational product, information from previous human experience may be available at the time of the initial IND submission and should be summarized, as it can provide valuable data on exposure and safety considerations; such data may come from the literature, use of the product for another indication, or foreign experience outside the U.S. Taken together, these data enable FDA to assess whether the clinical trial design will expose participants to unnecessary risks.
- Nonclinical: Nonclinical studies include a variety of in vitro assays and in vivo studies in animal models that are used to characterize the toxicity profile of a drug and support the safety of a clinical trial. Findings from IND-enabling pharmacology and toxicology studies are used to determine a safe starting dose for a clinical trial and establish the safety parameters to be monitored.
- Clinical Pharmacology: Depending on the extent of previous human experience with the investigational drug, clinical pharmacology data available at the IND stage may be limited. However, it is expected that a Sponsor will have identified the main enzyme(s) responsible for drug metabolism based on in vitro studies. Analytical methods planned for use in determining drug concentrations in biological samples (e.g., blood, plasma, urine) should be validated at this time and plans should be in place to collect pharmacokinetic samples in the proposed study according to an appropriate schedule. This information is important for evaluating systemic exposure to a drug and determining appropriate dosing strategies moving forward. Later in development, clinical pharmacology studies are aimed at identifying potential drug-drug interactions and assessing how other factors, such as age, genetic polymorphisms, or disease state can impact a drug’s effects.
- Chemistry, manufacturing, and controls: CMC information characterizes the identity (e.g., based on physical/chemical properties), purity, and stability of the investigational product; it also describes the manufacturing process and controls used for making a drug. The CMC information included in an IND should demonstrate that the overall quality of the product is suitable for use in human participants and can be manufactured consistently for the proposed clinical trial.
The Investigator’s Brochure summarizes this core information, as relevant to the conduct of the proposed study, and is submitted in the IND. It is also provided to clinical investigators and other study personnel to support their understanding of the investigational product, the study rationale and design, and to assist with safely managing study participants. Additional documents outlined in 21 CFR 312.23 include an Introductory Statement (briefly summarizing the investigational product and any previous human experience) and a General Investigational Plan (summarizing the Sponsor’s plans for the coming year).
THE IND APPLICATION
An IND is a formal request to FDA to allow a Sponsor to conduct human research with a new investigational product.
AT A GLANCE
Preparing for an IND
▸Can take months to years to conduct nonclinical studies and prepare all documents
▸IND-enabling nonclinical studies generate pharmacology and toxicology information to support safety of a clinical trial
▸Investigational products manufactured and stability studies are conducted
▸A clinical protocol is needed to open an IND
▸The Electronic Common Technical Document (eCTD) is the format that must be used for a commercial IND application
Application Cost
There is no filing cost to submit an IND
FDA Review Timeline
30 days for response
Possible Responses
Study may proceed OR clinical hold
Once an IND has been submitted to the appropriate Division, a 30-day review period is initiated, and the Sponsor may not initiate the clinical trial until the end of this review period. During this time, FDA reviewers assess the safety of the proposed clinical trial protocol, including doses, dose escalation, and safety monitoring plans, as well as whether the submitted nonclinical and CMC data support the proposed study design. The goals of an IND review are to determine whether the risks to participants are acceptable, safety monitoring is adequate, and design of the trial can meet its intended objectives. The benefit-risk profile is weighed, and if the proposed clinical trial is deemed acceptable, a letter indicating that the clinical trial is safe to proceed will be issued to indicate that clinical investigation may begin. Deficiencies in an IND, such as insufficient information to assess risks to humans or if participants would be exposed to unreasonable and significant risks, can result in the IND being placed on Clinical Hold meaning that the investigational product may not be administered to participants in the proposed study. Once all identified issues are sufficiently addressed and FDA removes the clinical hold, the clinical trial may proceed with enrolling participants and administering the investigational product.
Overall, preparing an IND requires a collaborative, multidisciplinary approach to ensure the application includes all necessary information to support the proposed clinical trial and aligns with the most appropriate regulatory strategy for continued development. While interactions with the FDA prior to an IND submission are incredibly valuable (and encouraged), early engagement with experienced regulatory professionals can be instrumental for developing efficient regulatory strategies, supporting FDA interactions, and ensuring the preparation and submission of compliant INDs. For example, a comprehensive gap analysis that considers the nuances of each development program can be a valuable tool to assess IND readiness and can provide specific guidance and mitigation strategies that can be used to overcome obstacles and achieve intended goals.
Salamandra has a host of clinical, scientific, and regulatory experts well versed in the expectations for INDs across a wide array of drug targets, novel drug structures, and therapeutics areas. If you have questions about IND applications or need assistance with pre-IND activities, such as a gap analyses, or the preparation of an IND, reach out to us at hello@salamandra.net.
This article is Part 1 of a series to explore expectations and requirements for early drug development from the nonclinical, clinical pharmacology, clinical, and CMC perspectives.
Part 1 ▸ What is an IND?
Part 2 ▸ How a Nonclinical Program Can Help Identify and Mitigate Risks
Part 3 ▸ Driving Efficiency in Early‑Phase Drug Development with Clinical Pharmacology
Part 4 ▸ Healthy Volunteers or Patients? A Key First-in-Human Decision